Agenus Inc (AGEN) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Agenus reported revenue of $114.2M, up 10.4% from $103.5M the year before. Net income was $115,000 (a 0.1% net margin). Gross margin was 99.1% and operating margin was -17.7%. Operating activities generated -$77.2M of cash, leaving -$77.2M of free cash flow. At fiscal year end, Agenus held $226.8M in total assets against $497.9M in total liabilities, including $3.0M of cash and equivalents.
Open the full interactive Agenus financials → Quarterly statements, key ratios, valuation history and price charts.
Agenus Key Stats
| Share Price | $6.95 |
|---|---|
| Market Cap | $287.3M |
| Revenue YoY Growth | +10.4% |
| 52-Week Range | $2.77 – $9.93 |
| Shares Outstanding | 41.3 million (basic, 2026 Q2) |
Agenus Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $88.2M | $295.7M | $98.0M | $156.3M | $103.5M | $114.2M |
| Gross Profit | $85.8M | $292.2M | $87.5M | $153.2M | $103.0M | $113.2M |
| Operating Income | -$117.2M | $25.7M | -$179.4M | -$159.5M | -$120.5M | -$20.2M |
| Pre-Tax Income | -$37.7M | -$23.9M | -$220.1M | -$245.8M | -$227.2M | -$3.1M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$37.7M | -$23.9M | -$220.1M | -$245.8M | -$227.2M | $115,000 |
| Diluted EPS | -$21.00 | -$2.20 | -$15.60 | -$13.80 | -$10.59 | — |
Agenus Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $30.2M | $34.2M | $33.7M | $34.5M |
| Net Income | $63.9M | -$10.6M | $39.2M | -$550,000 |
| Diluted EPS | $1.94 | -$0.36 | $1.02 | -$0.01 |
Agenus Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $99.9M | $291.9M | $178.7M | $76.1M | $40.4M | $3.0M |
| Current Assets | $113.8M | $332.0M | $213.1M | $112.4M | $45.6M | $133.4M |
| Total Assets | $214.5M | $466.0M | $413.6M | $313.9M | $226.3M | $226.8M |
| Current Liabilities | $129.9M | $156.9M | $189.0M | $255.9M | $221.4M | $323.5M |
| Total Long-Term Debt | $19.7M | $13.6M | $13.2M | $12.9M | $33.2M | $89.3M |
| Total Liabilities | $418.2M | $431.5M | $474.8M | $474.2M | $552.7M | $497.9M |
| Shareholders' Equity | -$203.7M | $34.4M | -$61.3M | -$160.3M | -$326.4M | -$271.1M |
Agenus Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$139.1M | $10.1M | -$175.4M | -$224.2M | -$158.3M | -$77.2M |
| Cash From Investing | -$4.4M | -$43.1M | -$33.6M | $3.4M | $27,000 | $1.2M |
| Cash From Financing | $183.9M | $225.3M | $95.8M | $119.9M | $122.8M | $36.6M |
| Free Cash Flow | -$142.6M | -$23.7M | -$228.4M | -$234.2M | -$158.9M | -$77.2M |
Figures from Agenus' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Agenus financials page for every line item.
Agenus Company Profile
| Ticker | AGEN |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Lexington, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer, smaller reporting company |
| SEC CIK | 0001098972 |
Frequently Asked Questions
What was Agenus' revenue in fiscal 2025?
Agenus (AGEN) reported revenue of $114.2M for fiscal 2025.
What is Agenus' annual revenue history?
Agenus' annual revenue by fiscal year: 2020: $88.2M; 2021: $295.7M; 2022: $98.0M; 2023: $156.3M; 2024: $103.5M; 2025: $114.2M.
What was Agenus' net income in fiscal 2025?
Agenus reported net income of $115,000 for fiscal 2025.
How much free cash flow did Agenus generate in fiscal 2025?
Agenus generated -$77.2M of free cash flow in fiscal 2025.
What was Agenus' revenue last quarter?
In its most recent reported quarter (2026 Q2), Agenus reported revenue of $34.5M.
How much debt does Agenus have?
Agenus reported $89.3M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Agenus are outstanding?
Agenus reported a weighted average of 41.3 million basic shares outstanding in 2026 Q2.
What is Agenus' market cap?
Based on its latest closing price, Agenus (AGEN) has a market capitalization of about $287.3M.
When does Agenus' fiscal year end?
Agenus' fiscal year end, as registered with the SEC, is December 31.
Where is Agenus headquartered?
Agenus lists its business address in Lexington, Massachusetts in its SEC filings.
Agenus Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →